In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Outlook Therapeutics Inc (NASDAQ: OTLK) closed the day trading at $1.46 up 1.39% from the previous closing price of $1.44. In other words, the price has increased by $1.39 from its previous closing price. On the day, 2.92 million shares were traded. OTLK stock price reached its highest trading level at $1.54 during the session, while it also had its lowest trading level at $1.4.
Ratios:
For a better understanding of OTLK, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.54 and its Current Ratio is at 0.67.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OTLK now has a Market Capitalization of 64852512 and an Enterprise Value of 90649400. For the stock, the TTM Price-to-Sale (P/S) ratio is 42.95. Its current Enterprise Value per Revenue stands at 60.219 whereas that against EBITDA is -1.25.
Stock Price History:
The Beta on a monthly basis for OTLK is 0.54, which has changed by -0.71984434 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, OTLK has reached a high of $6.98, while it has fallen to a 52-week low of $0.79. The 50-Day Moving Average of the stock is -0.61%, while the 200-Day Moving Average is calculated to be -12.51%.
Shares Statistics:
Over the past 3-months, OTLK traded about 3.71M shares per day on average, while over the past 10 days, OTLK traded about 2244180 shares per day. A total of 43.48M shares are outstanding, with a floating share count of 29.09M. Insiders hold about 34.52% of the company’s shares, while institutions hold 20.61% stake in the company. Shares short for OTLK as of 1759190400 were 4436035 with a Short Ratio of 1.20, compared to 1756425600 on 6807948. Therefore, it implies a Short% of Shares Outstanding of 4436035 and a Short% of Float of 12.1300004.
Earnings Estimates
. The current assessment of Outlook Therapeutics Inc (OTLK) involves the perspectives of 4.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.09 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$1.72 and -$1.92 for the fiscal current year, implying an average EPS of -$1.84. EPS for the following year is -$1.01, with 4.0 analysts recommending between -$0.28 and -$1.67.
Revenue Estimates
For the next quarter, 4 analysts are estimating revenue of $4.4M. There is a high estimate of $5M for the next quarter, whereas the lowest estimate is $3.8M.
Based on 5 analysts’ estimates, the company’s revenue will be $29.78M in the next fiscal year. The high estimate is $60.88M and the low estimate is $15.92M.
